The research team, led by Miranda A. Farage of The Procter and Gamble Company and DermatoSciences in Cincinnati and Inna Eiberger of Procter and Gamble in Germany, mined de-identified electronic health records, claims databases, hospital data, and pharmacy records from the United States covering more than 160 million individuals. Searching for the term sensitive skin alongside relevant ICD-10 diagnosis codes returned nearly 3.65 million records, of which 59,702 were linked to the term. After filtering for complete datasets, 2,333 subjects remained for analysis, with data collected between October 2019 and September 2022. A quota-sampled subset of 240 patients underwent deeper medical chart curation to characterize symptoms, treatments, and outcomes.

The demographic profile of the cohort was striking. Sixty-eight percent were female, consistent with the established female predominance in sensitive skin, and 81 percent were White. Ages spanned all adult groups, with 15 percent aged 18 to 34, 35 percent aged 35 to 54, 22 percent aged 55 to 64, and 28 percent aged 65 or older. At the index date, the first visit that generated a diagnosis code, 48 percent had no recorded comorbidities. But cardiovascular disease, present in 26 percent, and type 2 diabetes, present in 12 percent, were the two most common conditions, and both are established drivers of peripheral neuropathy. Six months later, cardiovascular disease appeared in 50 percent of the cohort, type 2 diabetes in 22 percent, sleep disturbance in 29 percent, and depressive episodes in 24 percent, all higher than in the general electronic health record population.

The diagnostic breakdown revealed the crux of the study. Forty-four percent of subjects received a dermatitis diagnosis, 15 percent had dry skin or urticaria, and 13 percent had acne, categories that clearly reflect genuine skin conditions. But 33 percent were diagnosed with altered skin sensation, a category that maps directly onto neurological territory. Within this group, 18 percent reported paresthesia or tingling, 11 percent reported anesthesia or numbness, and 4 percent reported other sensory symptoms. These are textbook peripheral neuropathy complaints, typically described as pins-and-needles, electric shock-like sensations, or burning pain that begins in the feet and progresses to the hands in a stocking-glove distribution.

Age stratification sharpened the signal. The prevalence of every sensory subcategory rose with advancing age: among those 65 and older, paresthesia reached 21 percent, anesthesia 13 percent, and other symptoms 5 percent, compared with just 9, 7, and 1 percent respectively in the youngest group. This gradient mirrors the epidemiology of peripheral neuropathy, which affects up to 15 percent of adults over 40 worldwide and climbs steeply with age. It also contrasts with sensitive skin itself, whose self-reported prevalence tends to decline with age even as severity increases. The authors argue that this age-related pattern is more consistent with a progressive nerve disorder than with a cosmetic or dermatological phenomenon.

Body localization added further nuance. Younger subjects reported symptoms predominantly on the face, the classic territory of sensitive skin, where cosmetics and procedures are most often implicated. But older groups showed a marked shift toward the extremities: symptoms on the arms rose from 13 percent in the youngest group to 27 percent in the middle group and 25 percent in the oldest, while leg involvement climbed from 11 to 21 percent and foot involvement from 2 to 10 percent. Men reported altered skin sensation more frequently than women, 31 versus 11 percent in the curated subset, and were more likely to report symptoms on the arms, legs, hands, and feet. Male sex has been identified as a predictor of peripheral neuropathy in some studies, possibly reflecting higher rates of diabetes, obesity, and smoking.

Treatment patterns exposed a diagnostic vacuum. Among patients with altered skin sensation, 68 percent received no treatment at all. Those who did were most often prescribed antihistamines, leukotriene receptor antagonists, systemic corticosteroids, or local anesthetics, none of which address nerve pathology. Only 7 percent of the overall cohort consulted a dermatologist, while 44 percent saw family or general practice physicians and 9 percent saw internal medicine specialists, suggesting that many patients and clinicians were uncertain which specialty should own the problem. The authors note that roughly 14 to 18 percent of patients continued to report relapse or worsening of symptoms over time, and that the etiology of sensitive skin was unknown in 60 percent of curated cases.

The study is careful to frame its conclusions as hypothesis-generating rather than definitive. Because the hypothesis of a sensitive skin to neuropathy link arose from inspection of the same dataset used to explore it, no formal statistical test was possible, and all analyses were descriptive. The quota-sampled subset is not generalizable to the full cohort, retention of only complete records introduces selection bias, and the collection window overlapped the COVID-19 pandemic, which may have distorted care-seeking and coding practices. Thermal sensory data, which would be critical for identifying small-fiber neuropathy, were absent from the source records. The pooled localization pattern, with the face among the most affected sites and foot involvement low, does not fit classic length-dependent neuropathy, and the authors restrict their neuropathy interpretation to the extremity-predominant subset.

Alternative explanations remain on the table, including localized neuropathic conditions such as notalgia paresthetica and brachioradial pruritus, entrapment neuropathies, radiculopathy, medication effects, primary dermatological disease, psychosomatic contributors, and simple coding artifacts. The authors also acknowledge that a type 2 diabetes prevalence of 12 percent at the index date is not clearly above the expected background for a cohort in which roughly half are aged 55 or older, so the findings are compatible with a mixed-etiology neuropathy rather than a predominantly diabetic one. Cardiovascular disease, metabolic syndrome, smoking, and age are all recognized non-diabetic contributors to peripheral nerve damage.

Nevertheless, the convergence of evidence, sensory symptoms that overlap with neuropathy, an age gradient matching neuropathy epidemiology, extremity-predominant localization in older patients, male predominance in the altered sensation subgroup, and comorbidities that are established neuropathy risk factors, raises the possibility that a subset of patients labeled with sensitive skin are actually harboring unrecognized peripheral neuropathy, potentially small-fiber neuropathy, which some researchers have proposed as a low-noise form of the condition. Prior work has shown that patients with sensitive skin have higher neuropathic pain scores and lower heat pain thresholds than controls, implicating damaged unmyelinated C-fibers, and hyperactive transient receptor potential channels on keratinocytes have been implicated in both conditions. The authors call for prospective, objectively phenotyped studies using tools such as quantitative sensory testing, corneal confocal microscopy, and skin biopsy, alongside validated questionnaire-based screening instruments, to confirm whether the association is genuine and clinically actionable. If it is, raising clinicians’ index of suspicion for peripheral neuropathy in patients presenting with sensitive-skin complaints, particularly extremity symptoms in older patients, could prevent years of diagnostic delay, inappropriate treatment, and progressive nerve damage.

Subject of Research: neuroscience

Article Title: Beyond the skin surface: untangling sensitive skin syndrome and peripheral neuropathy through an exploratory real-world data analysis

Article References: Farage, M. A., & Eiberger, I. (2026). Beyond the skin surface: untangling sensitive skin syndrome and peripheral neuropathy through an exploratory real-world data analysis. Frontiers in Pain Research, 7, Article 1883218. https://doi.org/10.3389/fpain.2026.1883218

Image Credits: AI Generated

DOI: 10.3389/fpain.2026.1883218

Keywords: peripheral neuropathy, sensitive skin syndrome, small-fiber neuropathy, real-world evidence, misdiagnosis, paresthesia, diabetes, dermatology, Beyond, skin, surface, untangling

The study drew on data from 356 women who had been diagnosed with breast cancer and were interviewed five years later as part of the VICAN5 survey, a large French national cohort designed to follow cancer survivors’ lives across health, work, and psychosocial domains. To characterize sexual dysfunction, the researchers selected five items from the Relationship and Sexuality Scale, a validated instrument covering dimensions of sexual life relevant to cancer survivors. Because sexual dysfunction is multidimensional, encompassing desire, arousal, comfort, and satisfaction, the team applied latent class analysis, a data-driven method that identifies unobserved subgroups within a population based on patterns of responses across multiple indicators. Instead of imposing arbitrary cutoff scores, latent class analysis lets the data reveal how symptoms cluster together in real people.

The analysis pointed decisively to a three-class model. The largest group, comprising 133 women or 37.4 percent of the sample, experienced moderate sexual dysfunction. A second group of 124 women, or 34.8 percent, reported no or low dysfunction. But the third group, 99 women representing 27.8 percent of survivors, reported high sexual dysfunction five years after diagnosis. In other words, nearly two-thirds of women in remission carried at least a moderate burden of sexual problems, and more than one in four carried a heavy one, at a point in their care when routine oncology follow-up has typically shifted focus to surveillance for recurrence rather than quality-of-life issues.

To understand what distinguished women in the higher-severity classes, the researchers used ordinal logistic regression, a statistical approach suited to outcomes that fall into ordered categories, in this case the ordered severity classes of dysfunction. The strongest association by far was psychological: women who reported feeling less sexually attractive had nearly five times the odds of belonging to a higher dysfunction class, with an adjusted odds ratio of 4.72. This finding places body image at the center of the sexual health picture for breast cancer survivors, consistent with a broader literature linking surgical scars, hair loss, weight changes, and altered breast sensation to diminished sexual self-concept and avoidance of intimacy.

Treatment exposures also left measurable marks. Women who had received radiotherapy had 2.36 times the odds of higher dysfunction, and those still taking adjuvant endocrine therapy at the time of the survey had 1.87 times the odds. Endocrine therapies, including tamoxifen and aromatase inhibitors, are taken for years and work by suppressing estrogen signaling, which can induce menopausal symptoms such as vaginal dryness, hot flashes, and decreased libido even in premenopausal women. The finding that current endocrine therapy use remained associated with sexual dysfunction at five years underscores that these drugs’ side effects are not transient inconveniences but persistent burdens that can erode adherence and quality of life.

Persistent physical symptoms emerged as another cluster of risk factors. Women reporting frequent excessive sweating had 1.67 times the odds of higher dysfunction, and those with frequent paresthesia, abnormal tingling or numbness in the breast or arm, had 1.78 times the odds. Both symptoms point to lasting physiological changes from treatment: vasomotor instability driven by endocrine effects, and nerve injury or sensory loss following surgery and radiation. Breast and nipple sensation plays a documented role in sexual response, and its loss is increasingly recognized as a distinct outcome, sometimes described as sensorisexual function, that deserves attention in its own right rather than being dismissed as a minor sensory change.

The analysis also flagged factors that might be modifiable. Women diagnosed after age 50 had 2.30 times the odds of higher dysfunction, a finding that likely reflects the interplay of natural menopause with treatment-induced hormonal changes. Frequent alcohol consumption was associated with 2.00 times the odds, and use of hypnotic medications, typically prescribed for sleep disturbance, with 1.66 times the odds. The hypnotic finding is particularly intriguing because sedative-hypnotic drugs have known effects on sexual function, and sleep disorders themselves are linked to sexual problems in women. Whether hypnotics are a cause, a marker of underlying distress, or both cannot be resolved in a cross-sectional analysis, but the association suggests that sleep management in survivors may have benefits that extend beyond rest.

The VICAN5 cohort itself deserves attention as a model for survivorship research. Funded by the French National Institute of Cancer, the VICAN surveys followed nationally representative samples of cancer patients at two and five years after diagnosis, capturing not only clinical outcomes but employment, social life, and intimate relationships. This breadth allowed the current analysis to situate sexual dysfunction within women’s whole lives rather than within the clinic alone. The study was approved by French ethics and data protection authorities, and all participants gave informed consent, meeting the standards expected of research touching on highly personal subject matter.

Certain limitations temper the conclusions. The analysis is cross-sectional, meaning it captures a single snapshot at five years and cannot establish whether the associated factors preceded the dysfunction or followed from it. The five RSS items, while validated, provide a narrower window on sexual function than comprehensive instruments such as the Female Sexual Function Index, and the sample of 356 women, though drawn from a national survey, may not represent all survivors, particularly those who declined to answer questions about sexuality. Sexual health questions are notoriously subject to underreporting, which means the true prevalence of dysfunction could be even higher than the study suggests.

Even with those caveats, the message for clinical practice is clear and increasingly urgent. The authors argue that sexual health assessment should be built into routine survivorship care for breast cancer, including dedicated oncosexual consultations, psychosexual support for body image concerns, and active management of persistent treatment symptoms such as vasomotor complaints and neuropathic sensations. Recent trials of newer agents for endocrine-therapy-related vasomotor symptoms show that effective options are emerging, and evidence-based non-pharmacological approaches to sleep and distress are available. What has been missing, the study implies, is the will to ask. Most survivors are never asked about their sexual lives by their oncology teams, and most do not raise the topic themselves. A simple, structured screening question at follow-up visits, targeted especially at women reporting feeling less sexually attractive or struggling with persistent symptoms, could open a door that too many women have been left to face alone.

Subject of Research: Patterns and predictors of sexual dysfunction among breast cancer survivors five years after diagnosis

Article Title: Patterns of sexual dysfunction among breast cancer survivors five years after diagnosis: a latent class analysis of the French VICAN5 study

Article References: Radwan, E., Seguin, L., Provansal, M., Mancini, J., & Bouhnik, A.-D. (2026). Patterns of sexual dysfunction among breast cancer survivors five years after diagnosis: a latent class analysis of the French VICAN5 study. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02108-z

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02108-z

Keywords: breast cancer survivors, sexual dysfunction, latent class analysis, VICAN5, adjuvant endocrine therapy, body image, radiotherapy, paresthesia, vasomotor symptoms, survivorship care, hypnotic use, quality of life